Article Text

Download PDFPDF
Quality of life in immune thrombocytopenia following treatment
  1. John D Grainger1,
  2. Nancy L Young2,
  3. Victor S Blanchette3,
  4. Robert J Klaassen4
  1. 1Department of Haematology, University of Manchester, Royal Manchester Children's Hospital, Manchester, UK
  2. 2School of Rural and Northern Health, Laurentian University, Sudbury, Ontario, Canada
  3. 3Hospital for Sick Children, Toronto, Ontario, Canada
  4. 4Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
  1. Correspondence to Dr John D Grainger, Department of Haematology, University of Manchester, Royal Manchester Children's Hospital, Ward 84, Manchester M13 9WL, UK;{at}


Objective To determine the impact of therapy on the reported health-related quality of life (HRQoL) in children with primary immune thrombocytopenia (ITP) using the Kids ITP tool (KIT).

Design Secondary data analysis of the international and North American KIT validation studies.

Results 217 children from 6 countries participated in the two studies. The majority of treatments occurred in children with newly diagnosed ITP. There was no statistical difference in age, platelet count and bleeding severity at presentation in those who physicians chose to treat or observe. Self-reported KIT scores did not differ between the two groups. The KIT parent-proxy scores were significantly worse for newly diagnosed children receiving treatment, especially following prednisone.

Conclusions Treatment of ITP does not improve, and may worsen, the HRQoL of children with ITP as measured using the KIT.

  • Haematology
  • General Paediatrics
  • ITP
  • quality of life

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.